Comparison of Enoxaparin Dosing to Achieve Anti-Factor Xa Thromboprophylaxis Levels in Super Morbidly Obese Patients undergoing Bariatric Surgery: A Prospective Randomized Controlled trial

Phase 3

Recruiting

• Conditions: Enoxaparin dosing to achieve anti-Factor Xa thromboprophylaxis levels in super morbidly obese patients undergoing bariatric surgery; Bariatric surgery, Thromboprophylaxis, Enoxaparin, Anti-Factor Xa, Super morbid obesity

• Registration Number: TCTR20221227001
• Lead Sponsor: Research Affairs, Faculty of Medicine, Chulalongkorn University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-27
• Last Update Posted: 19 August 2024
• Study Completion: 2024-09-09

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

1. Obese patients with BMI over or equal 50 kg/m2, 2. Age between 18-60 years

Exclusion Criteria

1. BMI less than 50 kg/m2, 2. Severe co-morbidities, 3. Current used of anticoagulants, 4. Patient with creatinine clearance <30 ml/min

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Anti-factor Xa levels 4 hrs, 12 hrs after administration IU/ml

Secondary Outcome Measures

Name	Time	Method
DVT 30-days postoperation Duplex ultraosonography,Perioperative blood loss Intraoperative and postoperative period ml